Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paolo Tarantino, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nicolò E, Tarantino P, Curigliano G. Biology and Treatment of HER2-Low Breast Cancer. Hematol Oncol Clin North Am. 2023 Feb; 37(1):117-132. PMID: 36435605.
    Citations:    Fields:    Translation:Humans
  2. Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023 Jan 12. PMID: 36669993.
    Citations:    Fields:    
  3. Tarantino P, Tayob N, Tolaney SM. Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply. JAMA Oncol. 2023 Jan 01; 9(1):147-148. PMID: 36327124.
    Citations:    Fields:    
  4. Tarantino P. Lessons from recent trials of antibody-drug conjugates in breast cancer. Clin Adv Hematol Oncol. 2022 Dec; 20(12):719-722. PMID: 36469665.
    Citations:    Fields:    
  5. Tarantino P, Nicolò E, Curigliano G. Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer". Eur J Cancer. 2023 Jan; 179:149-151. PMID: 36371304.
    Citations:    Fields:    Translation:Humans
  6. Nicolò E, Repetto M, Boscolo Bielo L, Tarantino P, Curigliano G. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2? Cancer J. 2022 Nov-Dec 01; 28(6):436-445. PMID: 36383906.
    Citations:    Fields:    Translation:Humans
  7. Tarantino P, Tolaney SM. The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors. Cancer Res. 2022 10 17; 82(20):3659-3661. PMID: 36245247.
    Citations:    Fields:    Translation:Humans
  8. Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM. Emerging Targeted Therapies for Early Breast Cancer. Drugs. 2022 Sep; 82(14):1437-1451. PMID: 36207645.
    Citations:    Fields:    Translation:Humans
  9. Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, Nakhlis F, Bellon JR, Parker T, Strauss S, Jin Q, King TA, Overmoyer BA, Curigliano G, Regan MM, Tolaney SM, Lynce F. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. Eur J Cancer. 2022 10; 174:277-286. PMID: 36116830.
    Citations:    Fields:    Translation:Humans
  10. Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer Discov. 2022 09 02; 12(9):2026-2030. PMID: 35856622.
    Citations:    Fields:    
  11. Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C, Curigliano G, Tolaney SM, Barroso-Sousa R. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences? Cancer Treat Rev. 2022 Nov; 110:102459. PMID: 35998514.
    Citations: 1     Fields:    Translation:Humans
  12. Schlam I, Tarantino P, Tolaney SM. Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers (Basel). 2022 Aug 18; 14(16). PMID: 36010990; PMCID: PMC9406173.
    Citations: 2     
  13. Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022 08 01; 8(8):1177-1183. PMID: 35737367; PMCID: PMC9227690.
    Citations: 1     Fields:    
  14. Tarantino P, Parsons HA, Tolaney SM. Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer-Should We Go "All In"?-Reply. JAMA Oncol. 2022 08 01; 8(8):1221-1222. PMID: 35708676.
    Citations:    Fields:    
  15. Giugliano F, Valenza C, Tarantino P, Curigliano G. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced? Expert Opin Investig Drugs. 2022 Aug; 31(8):855-874. PMID: 35762248.
    Citations:    Fields:    Translation:Humans
  16. Crimini E, Repetto M, Tarantino P, Ascione L, Antonarelli G, Rocco EG, Barberis M, Mazzarella L, Curigliano G. Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers (Basel). 2022 Jun 29; 14(13). PMID: 35804968; PMCID: PMC9264928.
    Citations:    
  17. Nicolò E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, Cristofanilli M, Curigliano G. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022 May; 106:102395. PMID: 35468539.
    Citations:    Fields:    Translation:Humans
  18. Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. JAMA Oncol. 2022 04 01; 8(4):629-635. PMID: 35024766.
    Citations:    Fields:    Translation:Humans
  19. Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022 07; 24(7):809-817. PMID: 35305211.
    Citations: 1     Fields:    Translation:Humans
  20. Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022 Feb 18; 8(1):23. PMID: 35181659; PMCID: PMC8857212.
    Citations: 1     
  21. Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18. PMID: 35173164; PMCID: PMC8850608.
    Citations:    
  22. Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022 03; 163:35-43. PMID: 35032815.
    Citations: 1     Fields:    Translation:Humans
  23. Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G. Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opin Biol Ther. 2022 03; 22(3):345-348. PMID: 34930070.
    Citations: 3     Fields:    Translation:Humans
  24. Tarantino P, Barroso-Sousa R, Garrido-Castro AC, McAllister SS, Guerriero JL, Mittendorf E, Curigliano G, Tolaney SM. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Rev Anticancer Ther. 2022 Feb; 22(2):141-153. PMID: 34919490.
    Citations:    Fields:    Translation:Humans
  25. Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, Toi M, Andrè F, Curigliano G. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncol. 2021 Dec 01; 7(12):1873-1881. PMID: 34647966.
    Citations: 6     Fields:    Translation:Humans
  26. Crimini E, Corti C, Repetto M, Giugliano F, Antonarelli G, Tarantino P, Zagami P, Morganti S, Nicolò E, Uliano J, Curigliano G. Systemic Treatment of Ductal Carcinoma In Situ of the Breast. Chirurgia (Bucur). 2021 12; 116(5 Suppl):S97-S104. PMID: 34967317.
    Citations:    Fields:    Translation:Humans
  27. Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivanet G, Morganti S, Corti C, Tarantino P, Friedlaender A, Belli C, Minchella I, Locatelli M, Esposito A, Criscitiello C, Curigliano G. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers (Basel). 2021 Nov 20; 13(22). PMID: 34830983.
    Citations: 3     
  28. Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 03; 72(2):165-182. PMID: 34767258.
    Citations: 6     Fields:    Translation:Humans
  29. Tarantino P, Antonarelli G, Ascione L, Curigliano G. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opin Investig Drugs. 2022 Jun; 31(6):499-513. PMID: 34569405.
    Citations: 1     Fields:    Translation:Humans
  30. Antonarelli G, Giugliano F, Corti C, Repetto M, Tarantino P, Curigliano G. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31; 14(9). PMID: 34577584; PMCID: PMC8468026.
    Citations: 4     
  31. Tarantino P, Tolaney SM, Harbeck N, Cortes J, Curigliano G. Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? J Clin Oncol. 2021 11 10; 39(32):3541-3545. PMID: 34406849.
    Citations: 2     Fields:    Translation:Humans
  32. Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, Curigliano G, Ascierto PA. First line treatment of BRAF mutated advanced melanoma: Does one size fit all? Cancer Treat Rev. 2021 Sep; 99:102253. PMID: 34186441.
    Citations: 6     Fields:    Translation:HumansCells
  33. Tarantino P, Trapani D, Curigliano G. Mastering the Use of Novel Anti-HER2 Treatment Options. JCO Oncol Pract. 2021 10; 17(10):605-606. PMID: 34077256.
    Citations: 1     Fields:    
  34. Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021; 2(2):139-155. PMID: 36046143; PMCID: PMC9400740.
    Citations: 1     
  35. Attili I, Tarantino P, Passaro A, Stati V, Curigliano G, de Marinis F. Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer. 2021 04; 154:151-160. PMID: 33684660.
    Citations: 13     Fields:    Translation:Humans
  36. Corti C, Crimini E, Tarantino P, Pravettoni G, Eggermont AMM, Delaloge S, Curigliano G. SARS-CoV-2 vaccines for cancer patients: a call to action. Eur J Cancer. 2021 05; 148:316-327. PMID: 33770576; PMCID: PMC7904467.
    Citations: 36     Fields:    Translation:HumansCells
  37. Tarantino P, Curigliano G. Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. Breast Cancer Res Treat. 2021 04; 186(3):885-886. PMID: 33634418.
    Citations:    Fields:    Translation:Humans
  38. Tarantino P, Mazzarella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treat Rev. 2021 Mar; 94:102169. PMID: 33652262.
    Citations: 1     Fields:    Translation:Humans
  39. Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021 Mar; 159:103223. PMID: 33482345.
    Citations: 12     Fields:    Translation:Humans
  40. Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, Curigliano G. Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opin Biol Ther. 2021 02; 21(2):127-133. PMID: 33238772.
    Citations: 11     Fields:    Translation:Humans
  41. Conforti F, Tarantino P, Trillo P, Pala L, Zagami P, Pirola S, Di Venosa B, Catania C, Queirolo P, Pennacchioli E, Della Vigna P, Curigliano G, De Pas TM. Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treat Rev. 2021 Jan; 92:102133. PMID: 33296826.
    Citations: 3     Fields:    Translation:Humans
  42. Tarantino P, Prat A, Cortes J, Cardoso F, Curigliano G. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochim Biophys Acta Rev Cancer. 2021 01; 1875(1):188487. PMID: 33259892.
    Citations: 5     Fields:    Translation:Humans
  43. Tarantino P, Prat A, Curigliano G. New anti-HER2 agents for brain metastasis: histology-agnostic weapons? Breast Cancer Res Treat. 2021 Feb; 185(3):879-881. PMID: 33128191.
    Citations: 1     Fields:    Translation:Humans
  44. Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G, Criscitiello C, Locatelli M, Belli C, Bellomi M, Curigliano G. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. Eur J Cancer. 2020 11; 139:92-98. PMID: 32979647.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  45. Tarantino P, Curigliano G. Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. N Engl J Med. 2020 08 13; 383(7):694-695. PMID: 32786200.
    Citations:    Fields:    Translation:Humans
  46. Conforti F, Pala L, Bagnardi V, Specchia C, Oriecuia C, Marra A, Zagami P, Morganti S, Tarantino P, Catania C, De Marinis F, Queirolo P, De Pas T. EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectr. 2020 Dec; 4(6):pkaa064. PMID: 33344882; PMCID: PMC7737478.
    Citations: 2     Fields:    
  47. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020 06 10; 38(17):1951-1962. PMID: 32330069.
    Citations: 32     Fields:    Translation:Humans
  48. Tarantino P, Morganti S, Curigliano G. Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opin Biol Ther. 2020 09; 20(9):1009-1024. PMID: 32255704.
    Citations: 7     Fields:    Translation:Humans
  49. Tarantino P, Trapani D, Curigliano G. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic. Eur J Cancer. 2020 06; 132:8-10. PMID: 32305011.
    Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
  50. Tarantino P, Curigliano G. Defining the immunogram of breast cancer: a focus on clinical trials. Expert Opin Biol Ther. 2019 05; 19(5):383-385. PMID: 30892954.
    Citations: 6     Fields:    Translation:HumansCells
  51. Tarantino P, Trapani D, Morganti S, Ferraro E, Viale G, D'Amico P, Duso BA, Curigliano G. Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. Cancer Drug Resist. 2019; 2(1):43-52. PMID: 35582141; PMCID: PMC9019172.
    Citations: 1     
  52. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol. 2019; 1168:9-30. PMID: 31713162.
    Citations: 43     Fields:    Translation:Humans
  53. Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol. 2019 Jan; 133:171-182. PMID: 30661654.
    Citations: 25     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Tarantino's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (99)
Explore
_
Co-Authors (30)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.